212 related articles for article (PubMed ID: 28150519)
1. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J
PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473
[TBL] [Abstract][Full Text] [Related]
3. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
[TBL] [Abstract][Full Text] [Related]
4. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
Trials; 2015 Apr; 16():198. PubMed ID: 25925591
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration.
Wang Y; Wu H; Chen Y; Wang Q; Qian J; Ge J
Adv Ther; 2020 Oct; 37(10):4220-4232. PubMed ID: 32770531
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.
Adamski P; Ostrowska M; Sikora J; Obońska K; Buszko K; Krintus M; Sypniewska G; Marszałł MP; Koziński M; Kubica J
BMJ Open; 2017 Apr; 7(4):e013218. PubMed ID: 28446521
[TBL] [Abstract][Full Text] [Related]
7. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
8. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
Teng R; Muldowney S; Zhao Y; Berg JK; Lu J; Khan ND
Eur J Clin Pharmacol; 2018 Sep; 74(9):1141-1148. PubMed ID: 29850937
[TBL] [Abstract][Full Text] [Related]
10. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
11. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
[TBL] [Abstract][Full Text] [Related]
12. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
Asher E; Frydman S; Katz M; Regev E; Sabbag A; Mazin I; Abu-Much A; Kukuy A; Mazo A; Erez A; Berkovitch A; Narodistky M; Barbash I; Segev A; Beigel R; Matetzky S
Thromb Haemost; 2017 Apr; 117(4):727-733. PubMed ID: 28150850
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
Butler K; Teng R
J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
[TBL] [Abstract][Full Text] [Related]
15. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Storey RF; Angiolillo DJ; Bonaca MP; Thomas MR; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Braunwald E; Sabatine MS
J Am Coll Cardiol; 2016 Mar; 67(10):1145-1154. PubMed ID: 26965534
[TBL] [Abstract][Full Text] [Related]
16. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G
Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
Röshammar D; Bergstrand M; Andersson T; Storey RF; Hamrén B
Int J Clin Pharmacol Ther; 2017 May; 55(5):416-424. PubMed ID: 28139972
[TBL] [Abstract][Full Text] [Related]
18. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Waksman R; Maya J; Angiolillo DJ; Carlson GF; Teng R; Caplan RJ; Ferdinand KC
Circ Cardiovasc Interv; 2015 Jul; 8(7):e002232. PubMed ID: 26152562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
